MELANOMA

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers such as breast, kidney, ovarian, head and neck, colorectal, lung, and skin cancer. The main goal was to check safety and find the right dose. The …

This study tested a drug called tovorafenib in people aged 12 and older whose cancers had returned or worsened and had certain gene changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, so results are limited.

This study tested a combination of two drugs—ipilimumab (an approved immunotherapy) and epacadostat (an experimental pill)—in people with advanced melanoma that could not be removed by surgery or had spread. The goal was to see if the combination was safe and worked better than i…

This study tested whether adding relatlimab to nivolumab (both drugs that help the immune system fight cancer) works better than nivolumab alone to keep melanoma from returning after complete surgical removal. The trial enrolled over 1,000 people with stage III or IV melanoma tha…

This study looked at whether taking a pill containing gut bacteria (EDP1503) could make standard immunotherapy (pembrolizumab) work better for people with advanced melanoma. The study planned to include two groups: those new to immunotherapy and those whose cancer had stopped res…

This study tested whether adding an experimental drug (NT-I7) to an existing immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial enrolled 31 adults whose cancers had not responded t…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This study compares two combinations of drugs for people with advanced melanoma that has a specific genetic change (BRAF V600E/K) and has worsened after prior anti-PD-1 therapy. Participants receive either a three-drug combo (encorafenib, binimetinib, and pembrolizumab) or a two-…

This study tested whether adding an immunotherapy drug (PDR001) to two standard targeted drugs (dabrafenib and trametinib) could help people with advanced melanoma that has a specific BRAF gene change. The trial planned to include about 568 people but was stopped early. The main …

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific PALB2 gene mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stopped early, so results are …

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or delay cancer growth. The trial was ter…

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated e…

This study tested a new drug called modakafusp alfa, given alone or with another drug (pembrolizumab), in adults with advanced solid tumors or melanoma that had spread. The goal was to find safe doses and check for side effects. The trial was stopped early, but it aimed to see if…

This early-phase trial tested a drug called STI-3031, given directly into the lymph nodes or vessels using a special device, for people with in-transit melanoma (cancer that has spread through lymph channels but not yet to distant organs). The main goals were to find the safest d…

This early-phase study tested a new medicine, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The st…

This early-stage study tested an experimental oral drug called TNO155 in 227 adults with advanced solid tumors (like lung, skin, or esophageal cancer) that had stopped responding to standard treatments. The main goal was to find safe doses and understand side effects, both when g…

This study tested the drug imatinib in 13 adults with ocular melanoma that had spread to other parts of the body. The goal was to see if the drug could stop or slow tumor growth. The trial was stopped early, and results were limited.

This study tested whether adding radiotherapy to the immunotherapy drug pembrolizumab could better control advanced melanoma than pembrolizumab alone. It involved 17 adults with stage III or IV melanoma that had spread. The trial was terminated early, so results are limited.

This study tested a copycat version (biosimilar) of the cancer drug nivolumab (Opdivo®) combined with another drug (Yervoy®) in people with advanced melanoma that cannot be removed by surgery or has spread. The goal was to see if the biosimilar works as well and is as safe as the…

This early-stage trial tested a new drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have specific genetic changes (MAPK pathway). The study was stopped early, so results are limited. The goal was to find safe doses and see…

This early-phase study tested a combination of two drugs—ipilimumab (an approved immunotherapy) and MGN1703 (an experimental immune booster)—in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN17…

This study tested a new drug combination for people with metastatic melanoma (cancer that has spread). The goal was to find the safest dose of an experimental drug (APX005M) given directly into tumors, along with a standard immunotherapy (pembrolizumab) given through the blood. T…

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or no longer responded to standard treatments. The main goal was to check the drug's safety and side effects. The study was terminated early, so r…

This early-phase study tested a new drug, BT-001, injected directly into tumors of people with advanced solid cancers (like melanoma or lung cancer). Some participants also received the immunotherapy pembrolizumab. The goal was to check safety and find the right dose. The study w…

This study tested whether adding an experimental drug (CMP-001) injected directly into tumors to the standard immunotherapy nivolumab works better than nivolumab alone for people with advanced melanoma that cannot be removed by surgery or has spread. The trial was stopped early a…

This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 18 adults with melanoma or kidney cancer that had spread to the brain. All participants had already been treated with similar immunotherapy drugs. The goal was to see if the combination could shrink br…

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This early-stage study tested a new experimental drug (PF-07820435) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, skin, and kidney cancers. The goal was to check safety and find the right dose. Only 9 people took part before the study was…

This study tested whether a technique called axillary reverse mapping with lympho-venous bypass can prevent arm lymphedema (swelling) in people having lymph nodes removed for breast cancer or melanoma. The approach aimed to preserve or reroute the arm's natural drainage during su…

This study tested a vaccine called POL-103A in 504 people who had surgery for high-risk melanoma. The goal was to see if the vaccine could prevent the melanoma from returning. The trial was stopped early, so final results are not available.

This study looked at how the immune system responds during high-dose radiation therapy in people with liver, colorectal, melanoma, or kidney cancers. Researchers collected blood samples before, during, and after treatment to track immune cells and other markers. The goal was to l…

This study created a registry for people who survived cancer as young adults (ages 18-39). Researchers wanted to understand their levels of depression, anxiety, social support, and financial stress. Participants filled out online surveys every 6 to 12 months. The registry also he…